Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Guerry

Showing results (81-90 of 113) with videos related to

Pageof 12
Sort By:
Cancer Research|October 1, 1984
Immunoassay for melanoma-associated proteoglycan in the sera of patients using monoclonal and polyclonal antibodiesA H Ross, M Herlyn, C S Ernst, et al.
The New England Journal of Medicine|April 25, 1991
Survival and quality of life among patients receiving unproven as compared with conventional cancer therapyB R Cassileth, E J Lusk, D Guerry, et al.
Lancet (London, England)|January 21, 1984
Managing the dysplastic naevus syndromeM H Greene, W H Clark, M A Tucker, et al.
Cancer|May 1, 1997
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study GroupK K Anbari, L M Schuchter, L P Bucky, et al.
The Journal of Clinical Investigation|January 1, 1984
HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytesD Guerry, M A Alexander, M F Herlyn, et al.
Current Eye Research|January 1, 1984
Basic mechanisms underlying the production of photochemical lesions in the mammalian retinaW T Ham, H A Mueller, J J Ruffolo, et al.
Journal of the National Cancer Institute|December 20, 1989
Model predicting survival in stage I melanoma based on tumor progressionW H Clark, D E Elder, D Guerry, et al.
JAMA|May 14, 1997
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanomaM A Tucker, A Halpern, E A Holly, et al.
Melanoma Research|February 6, 2002
Rarity of CDK4 germline mutations in familial melanomaA M Goldstein, A Chidambaram, A Halpern, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 1, 1995
Recognition and classification of clinically dysplastic nevi from photographs: a study of interobserver variationP Hartge, E A Holly, A Halpern, et al.
Pageof 12

Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Cancer Research|October 1, 1984
Immunoassay for melanoma-associated proteoglycan in the sera of patients using monoclonal and polyclonal antibodiesA H Ross, M Herlyn, C S Ernst, et al.
The New England Journal of Medicine|April 25, 1991
Survival and quality of life among patients receiving unproven as compared with conventional cancer therapyB R Cassileth, E J Lusk, D Guerry, et al.
Lancet (London, England)|January 21, 1984
Managing the dysplastic naevus syndromeM H Greene, W H Clark, M A Tucker, et al.
Cancer|May 1, 1997
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study GroupK K Anbari, L M Schuchter, L P Bucky, et al.
The Journal of Clinical Investigation|January 1, 1984
HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytesD Guerry, M A Alexander, M F Herlyn, et al.
Current Eye Research|January 1, 1984
Basic mechanisms underlying the production of photochemical lesions in the mammalian retinaW T Ham, H A Mueller, J J Ruffolo, et al.
Journal of the National Cancer Institute|December 20, 1989
Model predicting survival in stage I melanoma based on tumor progressionW H Clark, D E Elder, D Guerry, et al.
JAMA|May 14, 1997
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanomaM A Tucker, A Halpern, E A Holly, et al.
Melanoma Research|February 6, 2002
Rarity of CDK4 germline mutations in familial melanomaA M Goldstein, A Chidambaram, A Halpern, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 1, 1995
Recognition and classification of clinically dysplastic nevi from photographs: a study of interobserver variationP Hartge, E A Holly, A Halpern, et al.
Pageof 12